Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.
- Medtronic invests $90 million in Anteris as part of $320 million capital raise
- Funding supports global PARADIGM trial for DurAVR transcatheter heart valve
- PARADIGM trial is a randomized controlled study comparing DurAVR to existing TAVR devices
- DurAVR designed with patented biomimetic ADAPT tissue technology
- Collaboration signals alignment on advancing TAVR innovation and patient outcomes
Strategic Investment Boosts Anteris’ Clinical Ambitions
Anteris Technologies Global Corp. has secured a significant strategic investment of US$90 million from Medtronic, the world’s largest medical technology company. This investment is part of a larger US$320 million aggregate capital raise, which includes an underwritten offering of common stock. The fresh capital will underpin Anteris’ ongoing global pivotal PARADIGM trial and accelerate the commercialisation of its DurAVR Transcatheter Heart Valve (THV).
Advancing the Future of TAVR
Both Anteris and Medtronic share a vision to reshape the Transcatheter Aortic Valve Replacement (TAVR) market by pushing the boundaries of valve design and clinical science. Their focus remains on durability, haemodynamics, and long-term patient outcomes; critical factors in improving treatment for aortic stenosis, a life-threatening narrowing of the aortic valve.
The DurAVR THV stands out as the first biomimetic valve designed to replicate the natural function of a healthy human aortic valve. It utilises Anteris’ patented ADAPT tissue technology, an FDA-cleared anti-calcification treatment that has been used clinically for over a decade in more than 55,000 patients worldwide. This innovation aims to improve valve performance and longevity compared to existing balloon-expandable TAVR devices.
The PARADIGM Trial – A Rigorous Test
The PARADIGM trial is a prospective, randomized controlled study enrolling approximately 1,000 patients globally. It compares the safety and effectiveness of the DurAVR valve head-to-head with commercially available TAVR devices. The trial’s primary endpoint focuses on a composite of all-cause mortality, stroke, and cardiovascular hospitalisation at one year post-procedure. Recruitment began in late 2025, marking a critical phase in Anteris’ path to regulatory approval and market entry.
Strategic Collaboration with Potential for Expansion
While the US$90 million investment is a clear endorsement of Anteris’ technology and clinical programme, the companies have indicated that this partnership could evolve into broader strategic collaboration areas. Medtronic’s Vice President of Structural Heart business highlighted the importance of differentiated innovation like DurAVR in defining the future of TAVR therapies.
Wells Fargo Securities acted as the sole placement agent for the Medtronic investment, underscoring the deal’s significance in the medical device investment landscape.
Looking Ahead
With this capital injection, Anteris is well-positioned to continue its research and development efforts, advance clinical evidence, and move closer to commercialising a potentially transformative heart valve technology. The collaboration with Medtronic also signals a vote of confidence from a global leader in cardiovascular innovation.
Bottom Line?
Anteris’ strengthened financial and strategic position sets the stage for pivotal clinical milestones and potential market disruption in TAVR.
Questions in the middle?
- How will the PARADIGM trial results influence regulatory approval timelines for DurAVR?
- What specific strategic areas might the Anteris-Medtronic collaboration expand into beyond investment?
- How will DurAVR’s biomimetic design impact long-term patient outcomes compared to existing TAVR devices?